Diffregen Overview

  • Founded
  • 2011
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 3

Diffregen General Information


Developer of therapeutics designed to stop the progression of cancer and activate the healthy immune system. The company's services uses active ingredients are based on Angiocidin, a protein which has been shown to activate monocytes and drive terminal differentiation of leukemia cells, enabling AML patients to get proper treatement against cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare
Primary Office
  • 440 Coldstream Drive
  • PA 19312
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Diffregen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 21-Feb-2018 Completed Startup
2. Grant 01-Jan-2013 00000 Completed Startup
1. Grant 01-Jan-2011 $100K Completed Startup
To view Diffregen’s complete valuation and funding history, request access »

Diffregen Executive Team (2)

Name Title Board Seat Contact Info
Deni Zodda Chief Executive Officer
George Tuszynski Ph.D Founder
To view Diffregen’s complete executive team members history, request access »

Diffregen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MassChallenge Accelerator/Incubator 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Science Center Accelerator/Incubator 000 0000 000000 0
To view Diffregen’s complete investors history, request access »